NASDAQ: SPRCScisparc Ltd Stock
$8.34-0.21 (-2.46%)
Updated Jun 15, 2026
SPRC Price
$8.34
Fair Value Price
-$0.43
Market Cap
$3.05M
52 Week Low
$2.98
52 Week High
$80.10
P/E
-0.26x
P/B
2.16x
P/S
2.71x
PEG
N/A
Dividend Yield
N/A
Revenue
$285.33k
Earnings
$3.82M
Gross Margin
73.7%
Operating Margin
2,380.61%
Profit Margin
1,422.8%
Debt to Equity
0.58
Operating Cash Flow
-$1M
Beta
0.76
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SPRC Overview
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SPRC's potential to beat the market
- SPRC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SPRC
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.59 | A | |
| $53.00 | A | |
| $16.00 | A |
Be the first to know about important SPRC news, forecast changes, insider trades & much more!
SPRC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPRC ($8.34) is overvalued by 2,036.47% relative to our estimate of its Fair Value price of -$0.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SPRC ($8.34) is not significantly undervalued (2,036.47%) relative to our estimate of its Fair Value price of -$0.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPRC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRC due diligence checks available for Premium users.
Valuation
SPRC fair value
Fair Value of SPRC stock based on Discounted Cash Flow (DCF)
Price
$8.34
Fair Value
-$0.43
Undervalued by
2,036.47%
SPRC ($8.34) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRC ($8.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPRC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.26x
Industry
16.41x
Market
14.3x
SPRC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.16x
Industry
4.89x
SPRC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPRC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
SPRC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SPRC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.4M
Liabilities
$775.9k
Debt to equity
0.58
SPRC's short-term assets ($1.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRC's short-term assets ($1.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SPRC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
SPRC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPRC vs Biotech Stocks
Scisparc Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.